Evaluating the Rapid Onset of Vasomotor Symptom Improvement and Safety Profiles of NK Receptor Antagonists

The discussion highlights the rapid onset of action seen in both SKYLIGHT and OASIS trials, where patients experienced significant relief within the first few weeks. This immediacy enhances adherence, as patients quickly perceive therapeutic benefits.

Comparative safety analyses reveal low rates of serious adverse events, with mild liver enzyme elevations managed through routine monitoring. The balance of efficacy and safety positions NK antagonists as practical frontline therapies.

Panelists emphasize the importance of setting patient expectations, implementing liver function protocols, and reinforcing that early symptom relief contributes to long-term satisfaction and continued therapy.